RecruitingPhase 2NCT05361720

Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, OPTIC RCC Study

Studying Acquired cystic disease-associated renal cell carcinoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Vanderbilt-Ingram Cancer Center
Principal Investigator
Brian I Rini, MD
Vanderbilt University/Ingram Cancer Center
Intervention
Cabozantinib(drug)
Enrollment
54 enrolled
Eligibility
18 years · All sexes
Timeline
20222026

Study locations (6)

Collaborators

National Cancer Institute (NCI) · United States Department of Defense

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT05361720 on ClinicalTrials.gov

Other trials for Acquired cystic disease-associated renal cell carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Acquired cystic disease-associated renal cell carcinoma

← Back to all trials